Avenacy announced it has launched a suite of antibiotic products for injection, including:
- Ampicillin for Injection, USP
- Ampicillin and Sulbactam for Injection, USP
- Nafcillin for Injection, USP
- Penicillin G Potassium for Injection, USP
- Piperacillin and Tazobactam for Injection, USP
Combined, these products generated U.S. sales of approximately $175M for the twelve months ended September 30, 2024, representing a meaningful opportunity in the generic injectables market.
“The launch of these five antibiotic products further strengthens Avenacy’s foundational portfolio of high-usage, critical injectable products. I am proud of how swiftly this team has worked to successfully bring 20 important medications to the U.S. market, ”said Jeff Yordon, Co-Founder and CEO of Avenacy. “As we continue to focus on accelerating our growth, these antibiotic products will enable us to deepen our commercial presence in both the hospital and long-term/home health settings. With our growing antibiotic portfolio, we are well-positioned to drive continued market expansion that supports our long-term strategic objectives.”
In line with Avenacy’s mission to champion patient safety and streamline patient care, all five antibiotic products will feature the Company’s highly differentiated packaging and labeling to support accurate medication selection.
Avenacy will begin shipping all five antibiotics to wholesale partners next week. The Company is supported by a global network of development and contract manufacturing partners that have undergone successful FDA inspections based on cGMP-standards.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!